BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bohosova J, Vajcner J, Jabandziev P, Oslejskova H, Slaby O, Aulicka S. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy. Epilepsia 2021;62:2573-88. [PMID: 34486106 DOI: 10.1111/epi.17063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Stredny C, Rotenberg A, Leviton A, Loddenkemper T. Systemic inflammation as a biomarker of seizure propensity and a target for treatment to reduce seizure propensity. Epilepsia Open 2023;8:221-34. [PMID: 36524286 DOI: 10.1002/epi4.12684] [Reference Citation Analysis]
2 Shlobin NA, Sander JW. Current Principles in the Management of Drug-Resistant Epilepsy. CNS Drugs 2022;36:555-68. [PMID: 35590042 DOI: 10.1007/s40263-022-00922-4] [Reference Citation Analysis]
3 Manna I, Fortunato F, De Benedittis S, Sammarra I, Bertoli G, Labate A, Gambardella A. Non-Coding RNAs: New Biomarkers and Therapeutic Targets for Temporal Lobe Epilepsy. Int J Mol Sci 2022;23:3063. [PMID: 35328484 DOI: 10.3390/ijms23063063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 You J, Huang H, Chan CTY, Li L. Pathological Targets for Treating Temporal Lobe Epilepsy: Discoveries From Microscale to Macroscale. Front Neurol 2021;12:779558. [PMID: 35069411 DOI: 10.3389/fneur.2021.779558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]